- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Mortimore steps down as Merge CEO
After a dozen years at the helm of Merge Technologies, PACS and connectivity veteran Bill Mortimore has turned over the reins to Richard Linden. The move comes as part of a management restructuring that makes Linden president and CEO and Mortimore
After a dozen years at the helm of Merge Technologies, PACS and connectivity veteran Bill Mortimore has turned over the reins to Richard Linden. The move comes as part of a management restructuring that makes Linden president and CEO and Mortimore chairman and chief strategist.
In addition to founding Merge in 1987, Mortimore is one of the original members of the American College of Radiology/National Electrical Manufacturers Association (ACR/NEMA) committee responsible for establishing and maintaining the DICOM medical imaging standard. He also serves as chair of the Medical Imaging Informatics Section of NEMA and as a member of the board of directors of NEMAs diagnostic imaging division.
Under Mortimores leadership, Merge Technologies has moved from OEM-focused product distribution to a combination of OEM, value-added reseller, and direct sales. In addition, the firm has increased its core connectivity product portfolio (enabling the exchange of data in standard HL7 and DICOM formats between disparate legacy systems) to include Java-based text and image data exchange.
In his new position at Merge, Mortimore will turn his attention to advancing the strategic business and financial strategies of the Milwaukee-based firm, with particular emphasis on moving the company beyond its traditional clinical base into the broader healthcare environment.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
